Stockscreener 앱 받기
89.77
2.23%
-2.05
시간 외 거래:
89.77
전일 마감가:
$91.82
열려 있는:
$90.88
하루 거래량:
2.16M
Relative Volume:
2.03
시가총액:
$11.73B
수익:
$2.72B
순이익/손실:
$254.30M
주가수익비율:
43.44
EPS:
2.0665
순현금흐름:
$564.37M
1주 성능:
-8.04%
1개월 성능:
-16.33%
6개월 성능:
-24.72%
1년 성능:
-11.00%
1일 변동 폭
$88.53
$91.23
1주일 범위
$88.53
$97.98
52주 변동 폭
$88.53
$129.50
퍼킨엘머 Stock (RVTY) Company Profile
명칭
Revvity Inc
전화
781-663-6900
주소
77 4TH AVENUE, WALTHAM
RVTY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
89.77 | 11.73B | 2.72B | 254.30M | 564.37M | 2.0665 |
|
TMO
Thermo Fisher Scientific Inc
|
421.85 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
184.96 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
406.65 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
100.26 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
141.22 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
퍼킨엘머 Stock (RVTY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-10 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-15 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2024-08-28 | 개시 | Wells Fargo | Equal Weight |
| 2024-07-08 | 개시 | Leerink Partners | Outperform |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2024-01-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-01-04 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-07-19 | 개시 | Raymond James | Outperform |
| 2023-05-23 | 재개 | Goldman | Buy |
모두보기
퍼킨엘머 주식(RVTY)의 최신 뉴스
Earnings Preview: Revvity (RVTY) Q1 Earnings Expected to Decline - Yahoo Finance
Revvity (RVTY) Price Target Cut by Baird Ahead of Q1 Results | RVTY Stock News - GuruFocus
Bernstein Adjusts Price Target on Revvity to $120 From $140, Maintains Market Perform Rating - marketscreener.com
Revvity price target lowered to $120 from $140 at Bernstein - TipRanks
Lab equipment giant ensnared in sprawling $300M fraud case over failed testing tools - Green Market Report
Revvity (RVTY) Faces Price Target Cut Amid Funding Concerns | RV - GuruFocus
Ex-Dividend Reminder: Revvity, Dime Community Bancshares and First Busey - Nasdaq
What Is Revvity, Inc.'s (NYSE:RVTY) Share Price Doing? - Yahoo Finance
BofA Reduces Revvity (RVTY) Price Target Amid Policy Challenges - GuruFocus
BofA Securities Cuts Price Target on Revvity to $116 From $143, Maintains Buy Rating - MarketScreener
BofA Reduces Revvity (RVTY) Price Target Amid Policy Challenges | RVTY Stock News - GuruFocus
KeyBanc Lowers Price Target on Revvity to $135 From $145 - MarketScreener
Barclays Adjusts Revvity (RVTY) Price Target Ahead of Q1 Earnings | RVTY Stock News - GuruFocus
Barclays Adjusts Price Target on Revvity to $110 From $140 - MarketScreener
KeyBanc maintains Overweight rating on Revvity stock at $145 target - Investing.com Australia
KeyBanc maintains Overweight rating on Revvity stock at $145 target By Investing.com - Investing.com South Africa
KeyBanc Adjusts Price Target on Revvity to $145 From $135, Keeps Overweight Rating - MarketScreener
Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price - simplywall.st
Revvity Signals Software Unveils Unified Data Platform To Accelerate Drug Discovery - Technology Networks
Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test - Technology Networks
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now - MSN
Revvity Q1 2025 Earnings Preview: CEO and CFO to Detail Financial Performance - Stock Titan
FDA approves Revvity’s Auto-Pure platform and tuberculosis test combo - Yahoo
Revvity (RVTY) Gains FDA Approval for Automated TB Test - GuruFocus
FDA greenlights Revvity’s TB diagnostic platform By Investing.com - Investing.com South Africa
What's Going On With Revvity Stock Today? - Benzinga
(RVTY) Investment Analysis - news.stocktradersdaily.com
Evercore ISI Adjusts Revvity Price Target to $125 From $138, Maintains Outperform Rating - MarketScreener
FDA Approves Revvity’s Improved Automated Latent Tuberculosis Test - Medical Product Outsourcing
Revvity gets FDA nod for its automated tuberculosis test (RVTY:NYSE) - Seeking Alpha
Revvity Says FDA Approves Auto-Pure 2400 Liquid Handler for Tuberculosis Test - marketscreener.com
FDA greenlights Revvity’s TB diagnostic platform - Investing.com India
Revvity Secures FDA Approval For Improved Automated Latent Tuberculosis Test - MarketScreener
Game-Changing TB Test: Revvity's New FDA-Approved System Cuts Testing Time by 70% - Stock Titan
Pictet Asset Management Holding SA Has $125.17 Million Holdings in Revvity, Inc. (NYSE:RVTY) - MarketBeat
Is Revvity Stock Underperforming the Nasdaq? - MSN
High Content Screening/Imaging Technology Analysis and Global Market Forecasts 2025-2029 with Danaher, Revvity, Thermo Fischer Scientific, Agilent Technologies and Yokogawa LeadingResearchAndMarkets.com - Bluefield Daily Telegraph
Is Revvity Stock Underperforming The Nasdaq? - Barchart.com
Is Revvity Gaining or Losing Market Support? - Benzinga
Revvity Expands Alliance With Genomics England To Drive Research Into Newborn Genomic Sequencing in England - Technology Networks
Revvity Stock Tumbles Despite Expanding Genomics England Alliance - MSN
The total return for Revvity (NYSE:RVTY) investors has risen faster than earnings growth over the last five years - Yahoo Finance
Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England - BioSpace
Revvity Expands Alliance with Genomics England -March 20, 2025 at 02:10 pm EDT - MarketScreener
Massive Breakthrough: Revvity's 100K Newborn Genetic Screening Program Targets 200 Rare Diseases - StockTitan
May 16th Options Now Available For Revvity (RVTY) - Nasdaq
Should You Think About Buying Revvity, Inc. (NYSE:RVTY) Now? - Simply Wall St
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
퍼킨엘머 (RVTY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.18%
자본화:
|
볼륨(24시간):